Literature DB >> 1458783

Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

M Vayssairat1, N Baudot, N Abuaf, C Johanet.   

Abstract

To evaluate the usefulness of recently proposed schemes of classification for systemic sclerosis an extensive cross-sectional study of a series of 164 consecutive patients with long-term systemic sclerosis was undertaken. There were 47 cases of proximal sclerosis, 93 of distal sclerosis and 24 of complete CREST syndrome. The study included clinical, visceral, immunological and follow-up data. In addition, a quantitative clinical score was calculated for each patient, thus providing indications for prognosis. Data were expressed according to three conventional systems of classification: The ARA system, the diffuse versus limited systemic sclerosis system and the early cutaneous involvement system. The most reliable indications of severe outcome were: proximal sclerosis, trunk skin involvement, presence of anti Scl 70 autoantibody, pulmonary and/or heart involvement and age. Diagnosis and prognosis were not generated by the same items. Prognosis indicators proved more accurate for groups than for individuals. Mortality was 1 death per 149 patient X years of follow-up from diagnosis. We conclude that the ARA criteria for classification should be recognized as a standard, but patients with complete CREST syndrome should be included in the distal group. Other systems of classification, principally 2-way versus 3-way criteria, allow different subsets of patients that correlate with prognosis and the severity of the disease, and could be used for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458783     DOI: 10.1007/bf02207193

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  45 in total

1.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

2.  A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease.

Authors:  A J Barnett; M H Miller; G O Littlejohn
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Progressive systemic sclerosis sine scleroderma.

Authors:  G P RODNAN; R H FENNELL
Journal:  JAMA       Date:  1962-05-26       Impact factor: 56.272

4.  The prognosis of systemic sclerosis.

Authors:  N R Rowell
Journal:  Br J Dermatol       Date:  1976-07       Impact factor: 9.302

5.  Pitfalls in assessment of prognosis. Weak study designs are liable to bias.

Authors:  S M van der Linden; P Tugwell
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

6.  Scl 70 antibody--a specific marker of systemic sclerosis.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; S Jablonska; T Chorzelski; V Kumar; E H Beutner
Journal:  Br J Dermatol       Date:  1986-10       Impact factor: 9.302

7.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04

9.  Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).

Authors:  R Salerni; G P Rodnan; D F Leon; J A Shaver
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

10.  [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].

Authors:  C Johanet; M M Agostini; M Vayssairat; N Abuaf
Journal:  Presse Med       Date:  1989-02-11       Impact factor: 1.228

View more
  5 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  [The road to early diagnosis of systemic sclerosis : the evolution of diagnostic and classification criteria in the past decades].

Authors:  M Frerix; F M P Meier; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

4.  Mortality and causes of death in a Swedish series of systemic sclerosis patients.

Authors:  R Hesselstrand; A Scheja; A Akesson
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

Review 5.  The development of systemic sclerosis classification criteria.

Authors:  Jennifer G Walker; Janet Pope; Murray Baron; Sharon Leclercq; Marie Hudson; Suzanne Taillefer; Steven M Edworthy; Oleg Nadashkevich; Marvin J Fritzler
Journal:  Clin Rheumatol       Date:  2007-02-07       Impact factor: 3.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.